文献速递淋巴瘤

大型HIV相关霍奇金淋巴瘤患者队列中18F-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描的首次广泛分析:基线总代谢肿瘤体积影响预后

First Extensive Analysis of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in a Large Cohort of Patients With HIV-Associated Hodgkin Lymphoma: Baseline Total Metabolic Tumor Volume Affects Prognosis.
PubMed 文献 · J Clin Oncol · 2022-01-24

研究对109例HIV相关霍奇金淋巴瘤患者的基线18F-FDG PET-CT及104例中期PET进行中心审阅,患者自2007年起接受多柔比星、博来霉素、长春花碱和达卡巴嗪化疗。中位随访6.7年,5年无进展生存率75.1%,5年总生存率86.1%;基线总代谢肿瘤体积高是唯一独立与无进展生存相关的参数。

要点

  • 109例HIV相关霍奇金淋巴瘤患者中,30%为III期、43%为IV期,骨髓和肝脏为常见结外受累部位。
  • 基线总代谢肿瘤体积中位值为121.4 cm3,预后分析最佳截断值为527 cm3。
  • 总代谢肿瘤体积>527 cm3的20例患者2年无进展生存率71%,≤527 cm3的89例为91%(P = .004)。

核心结论

  • 在这组管理同质的HIV相关霍奇金淋巴瘤患者中,基线PET-CT显示高总代谢肿瘤体积与不良预后相关。

研究设计与样本

  • 对109例HIV相关霍奇金淋巴瘤患者的基线18F-FDG PET-CT及104例中期PET进行中心审阅,患者自2007年起接受多柔比星、博来霉素、长春花碱和达卡巴嗪化疗。
  • 所有患者均纳入一项正在进行的HIV相关淋巴瘤前瞻性单中心队列。

主要发现

  • 大多数患者按Ann Arbor分类为播散性疾病(30%为III期,43%为IV期),结外部位尤其以骨髓和肝脏为主。
  • 中位随访6.7年后,12例复发(11%),13例死亡(12%)。
  • 5年无进展生存率为75.1%,5年总生存率为86.1%。
  • 总代谢肿瘤体积中位值为121.4 cm3。
  • 总代谢肿瘤体积>527 cm3的20例患者2年无进展生存率为71%,而总代谢肿瘤体积≤527 cm3的89例患者为91%(P = .004)。

关键数值与推荐

  • 预后分析确定的总代谢肿瘤体积最佳截断值为527 cm3。
  • 总代谢肿瘤体积>527 cm3的20例患者2年无进展生存率为71%,总代谢肿瘤体积≤527 cm3的89例患者为91%(P = .004)。
  • 多因素分析中,高总代谢肿瘤体积是唯一独立与无进展生存相关的参数。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 18F-labeled fluorodeoxyglucose positron emission tomography with computed tomography (18F-FDG PET-CT) data in HIV-associated Hodgkin lymphoma (HIV-HL) are scarcely reported. In addition to the description of the characteristics of both baseline and interim 18F-FDG PET-CT examinations (PET1 and iPET, respectively), the aim of this study was to assess the prognostic value of PET1 and previously identified clinical parameters in this population. PATIENTS AND METHODS: PET1 of 109 patients with HIV-HL, treated with doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy regimen since 2007, and 104 iPET were centrally reviewed. All the patients were enrolled in an ongoing prospective single-center cohort of HIV-associated lymphoma. RESULTS: Most patients had a disseminated disease according to the Ann Arbor classification (30% stage III and 43% stage IV), with especially bone marrow and liver as extranodal localizations. After a median follow-up of 6.7 years, 12 patients relapsed (11%) and 13 died (12%). Five-year progression-free survival (PFS) was 75.1%, and 5-year overall survival was 86.1%. Median total metabolic tumor volume (TMTV) was 121.4 cm3. The optimal TMTV cutoff identified for prognostic analysis was 527 cm3, with a 2-year PFS of 71% in the 20 patients with TMTV > 527 cm3, compared with 91% in the 89 patients with TMTV ≤ 527 cm3 (P = .004). On multivariate analysis, a high TMTV was the only parameter independently associated with PFS. CONCLUSION: In this large series of HIV-HL patients with a homogeneous management, high TMTV on PET1 examination was associated with a poor prognosis.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Louarn N, Galicier L, Bertinchamp R, et al. First Extensive Analysis of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in a Large Cohort of Patients With HIV-Associated Hodgkin Lymphoma: Baseline Total Metabolic Tumor Volume Affects Prognosis. J Clin Oncol. 2022. PMID: 35073166. doi:10.1200/JCO.21.01228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。